To study the effect of LDHB in an immunocompetent and orthotopic setting, we used our established genetically engineered mouse model for NSCLC that combines an LDHB deletion allele with the inducible model of lung adenocarcinoma driven by concomitant loss of p53 (also known as Trp53) and expression of oncogenic KRAS (G12D) (KP)11. The gene discussed is KRAS; the disease is lung adenocarcinoma.